These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38543856)

  • 21. Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection.
    Pacheco-Herrero M; Soto-Rojas LO; Harrington CR; Flores-Martinez YM; Villegas-Rojas MM; León-Aguilar AM; Martínez-Gómez PA; Campa-Córdoba BB; Apátiga-Pérez R; Corniel-Taveras CN; Dominguez-García JJ; Blanco-Alvarez VM; Luna-Muñoz J
    Front Neurol; 2021; 12():660087. PubMed ID: 33912129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does SARS-CoV-2 infection cause chronic neurological complications?
    Hascup ER; Hascup KN
    Geroscience; 2020 Aug; 42(4):1083-1087. PubMed ID: 32451846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and glial cells: Insights and perspectives.
    Vargas G; Medeiros Geraldo LH; Gedeão Salomão N; Viana Paes M; Regina Souza Lima F; Carvalho Alcantara Gomes F
    Brain Behav Immun Health; 2020 Aug; 7():100127. PubMed ID: 32838339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19.
    Halaji M; Farahani A; Ranjbar R; Heiat M; Dehkordi FS
    Infez Med; 2020 Jun; 28(suppl 1):6-17. PubMed ID: 32532933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global Consortium.
    de Erausquin GA; Snyder H; Brugha TS; Seshadri S; Carrillo M; Sagar R; Huang Y; Newton C; Tartaglia C; Teunissen C; Håkanson K; Akinyemi R; Prasad K; D'Avossa G; Gonzalez-Aleman G; Hosseini A; Vavougios GD; Sachdev P; Bankart J; Mors NPO; Lipton R; Katz M; Fox PT; Katshu MZ; Iyengar MS; Weinstein G; Sohrabi HR; Jenkins R; Stein DJ; Hugon J; Mavreas V; Blangero J; Cruchaga C; Krishna M; Wadoo O; Becerra R; Zwir I; Longstreth WT; Kroenenberg G; Edison P; Mukaetova-Ladinska E; Staufenberg E; Figueredo-Aguiar M; Yécora A; Vaca F; Zamponi HP; Re VL; Majid A; Sundarakumar J; Gonzalez HM; Geerlings MI; Skoog I; Salmoiraghi A; Boneschi FM; Patel VN; Santos JM; Arroyo GR; Moreno AC; Felix P; Gallo C; Arai H; Yamada M; Iwatsubo T; Sharma M; Chakraborty N; Ferreccio C; Akena D; Brayne C; Maestre G; Blangero SW; Brusco LI; Siddarth P; Hughes TM; Zuñiga AR; Kambeitz J; Laza AR; Allen N; Panos S; Merrill D; Ibáñez A; Tsuang D; Valishvili N; Shrestha S; Wang S; Padma V; Anstey KJ; Ravindrdanath V; Blennow K; Mullins P; Łojek E; Pria A; Mosley TH; Gowland P; Girard TD; Bowtell R; Vahidy FS
    Alzheimers Dement (N Y); 2022; 8(1):e12348. PubMed ID: 36185993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible Link between SARS-CoV-2 Infection and Parkinson's Disease: The Role of Toll-Like Receptor 4.
    Conte C
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't.
    Lingor P; Demleitner AF; Wolff AW; Feneberg E
    J Neural Transm (Vienna); 2022 Sep; 129(9):1155-1167. PubMed ID: 35434769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 and Neurodegenerative Diseases: Prion-Like Spread and Long-Term Consequences.
    Baazaoui N; Iqbal K
    J Alzheimers Dis; 2022; 88(2):399-416. PubMed ID: 35599487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic Exchange of Lung-Derived Exosome to Brain Causing Neuronal Changes on COVID-19 Infection.
    Ahmed SSSJ; Paramasivam P; Kamath M; Sharma A; Rome S; Murugesan R
    Mol Neurobiol; 2021 Oct; 58(10):5356-5368. PubMed ID: 34312772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case Report: Neurodegenerative Diseases After Severe Acute Respiratory Syndrome Coronavirus 2 Infection, a Report of Three Cases: Creutzfeldt-Jakob Disease, Rapidly Progressive Alzheimer's Disease, and Frontotemporal Dementia.
    Pimentel GA; Guimarães TG; Silva GD; Scaff M
    Front Neurol; 2022; 13():731369. PubMed ID: 35197920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implication of Covid-19 on Neurological Complications with Specific Emphasis on Alzheimer's and Parkinson's Disease.
    Sood A; Goyal R; Singh H; Behl T; Arora S; Saini B; Kaur R
    CNS Neurol Disord Drug Targets; 2022; 21(3):235-245. PubMed ID: 34414876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Animal models for SARS-CoV-2 research: A comprehensive literature review.
    Pandey K; Acharya A; Mohan M; Ng CL; Reid SP; Byrareddy SN
    Transbound Emerg Dis; 2021 Jul; 68(4):1868-1885. PubMed ID: 33128861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
    Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J
    J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Mechanisms of SARS-CoV-2/COVID-19 Pathogenicity on the Central Nervous System: Bridging Experimental Probes to Clinical Evidence and Therapeutic Interventions.
    Groppa SA; Ciolac D; Duarte C; Garcia C; Gasnaș D; Leahu P; Efremova D; Gasnaș A; Bălănuță T; Mîrzac D; Movila A
    Adv Exp Med Biol; 2022; 1376():1-27. PubMed ID: 34735712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS.
    Szabo MP; Iba M; Nath A; Masliah E; Kim C
    Exp Mol Med; 2022 Apr; 54(4):447-454. PubMed ID: 35396576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the COVID-19 Pandemic on Chronic Neurological Disorders: Focus on Patients with Dementia.
    Barbieri MA; Bagnato G; Ioppolo C; Versace AG; Irrera N
    CNS Neurol Disord Drug Targets; 2022; 21(10):1017-1026. PubMed ID: 35021982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of a comprehensive dataset: Influence of vaccination profile, types, and severe acute respiratory syndrome coronavirus 2 re-infections on changes in sports-related physical activity one month after infection.
    Bourdas DI; Bakirtzoglou P; Travlos AK; Andrianopoulos V; Zacharakis E
    Data Brief; 2023 Dec; 51():109723. PubMed ID: 37965614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
    Ye ZW; Jin DY
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.
    Arevalo-Romero JA; Chingaté-López SM; Camacho BA; Alméciga-Díaz CJ; Ramirez-Segura CA
    Heliyon; 2024 Mar; 10(5):e26423. PubMed ID: 38434363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.